Please use this identifier to cite or link to this item: https://doi.org/10.5966/sctm.2013-0070
DC FieldValue
dc.titleHuman dendritic cells derived from embryonic stem cells stably modified with CD1d efficiently stimulate antitumor invariant natural killer T cell response
dc.contributor.authorZeng, J.
dc.contributor.authorWang, S.
dc.date.accessioned2014-10-27T08:30:43Z
dc.date.available2014-10-27T08:30:43Z
dc.date.issued2014
dc.identifier.citationZeng, J., Wang, S. (2014). Human dendritic cells derived from embryonic stem cells stably modified with CD1d efficiently stimulate antitumor invariant natural killer T cell response. Stem Cells Translational Medicine 3 (1) : 69-80. ScholarBank@NUS Repository. https://doi.org/10.5966/sctm.2013-0070
dc.identifier.issn21576564
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/100846
dc.description.abstractInvariant natural killer T (iNKT) cells are a unique lymphocyte subpopulation that mediates antitumor activities upon activation. Acurrent strategy to harness iNKT cells for cancer treatment is endogenous iNKT cell activation using patient-derived dendritic cells (DCs). However, the limited number and functional defects of patient DCs are still the major challenges for this therapeutic approach. In this study, we investigated whether human embryonic stem cells (hESCs) with an ectopically expressed CD1d gene could be exploited to address this issue. Using a lentivector carrying an optimized expression cassette, we generated stably modified hESC lines that consistently overexpressed CD1d. These modified hESC lines were able to differentiate into DCs as efficiently as the parental line. Most importantly, more than 50% of such derived DCs were CD1d+. These CD1d-overexpressing DCs were more efficient in inducing iNKT cell response than those without modification, and their ability was comparable to that of DCs generated from monocytes of healthy donors. The iNKT cells expanded by the CD1doverexpressing DCs were functional, as demonstrated by their ability to lyse iNKT cell-sensitive glioma cells. Therefore, hESCs stably modified with the CD1d gene may serve as a convenient, unlimited, and competent DC source for iNKT cell-based cancer immunotherapy. © AlphaMed Press 2014.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.5966/sctm.2013-0070
dc.sourceScopus
dc.subjectCD1d
dc.subjectDendritic cell
dc.subjectGenetic modification
dc.subjectImmunotherapy
dc.subjectInvariant natural killer T cell
dc.subjectStem cell
dc.typeArticle
dc.contributor.departmentBIOLOGICAL SCIENCES
dc.description.doi10.5966/sctm.2013-0070
dc.description.sourcetitleStem Cells Translational Medicine
dc.description.volume3
dc.description.issue1
dc.description.page69-80
dc.identifier.isiut000330014000008
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

5
checked on May 20, 2022

WEB OF SCIENCETM
Citations

6
checked on May 20, 2022

Page view(s)

83
checked on May 12, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.